Epclusa is a radical treatment for pangenotypic chronic hepatitis C, and its efficacy has been widely validated in clinical practice. As a potent antiviral drug, its use involves specific contraindications, drug interaction risks, and necessary monitoring indicators.
Precautions for Epclusa Use
Risk of Hepatitis B Virus Reactivation
(1) All patients must be screened for current or past hepatitis B virus infection by hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) testing before initiating Epclusa treatment.
(2) Hepatitis B virus reactivation may lead to fulminant hepatitis, liver failure, or even death.
(3) For patients with concurrent hepatitis B virus infection, hepatitis B virus markers and liver function should be monitored regularly throughout and after treatment.
(4) If a hepatitis flare-up or signs of viral reactivation occur, standard hepatitis B antiviral therapy should be initiated immediately.
Fatal Bradycardia with Amiodarone
(1) Epclusa should never be used in combination with the antiarrhythmic drug amiodarone, as this may lead to severe symptomatic bradycardia, especially in patients using beta-blockers, or those with underlying heart disease or advanced liver disease.
(2) When using a sofosbuvir-containing regimen (including Epclusa), if the patient is taking amiodarone.
(3) The patient should be informed in detail of the risk symptoms of bradycardia (such as syncope, dizziness, weakness, chest pain, dyspnea, or confusion). Hospitalized cardiac monitoring should be performed for 48 hours prior to co-administration, followed by daily heart rate monitoring for at least two weeks prior to treatment.
Key Drug Interactions to Avoid
(1) P-gp inducers/moderate-potency CYP inducers: such as rifampin, St. John's wort, carbamazepine. These drugs accelerate the metabolic clearance of sofosbuvir and/or velpatasvir.
(2) Antacids: Must be taken 4 hours apart from Epclusa.
(3) HIV antiviral drug Epclusa: Regimens containing Epclusa are contraindicated.
(4) H2 receptor antagonists (e.g., famotidine): Daily dose not exceeding 40 mg twice daily, and taken simultaneously with or 12 hours apart from Epclusa.
Epclusa (Epclusa) Medication Monitoring
Viral Response Monitoring
(1) Baseline Testing: Serum HCV RNA levels and viral genotyping must be measured before treatment.
(2) 4 Weeks of Treatment: HCV RNA should be retested to assess the viral response trend early.
(3) At the End of Treatment: Confirm whether the virus has become negative.
(4) 12 Weeks After Treatment: Assess sustained virological response (SVR12), which is the gold standard for clinical cure.
Dynamic Liver Function Monitoring
(1) Bilirubin (Focus on dynamic changes in direct bilirubin).
(2) Transaminase levels: ALT/AST levels fluctuate.
(3) Severity of cirrhosis: Child-Pugh or MELD scores are updated regularly.
